January 26, 2012 (San Francisco, California) — Results of a phase 3 randomized trial in metastatic colorectal cancer indicate that brivanib alaninate, an antivascular endothelial growth factor receptor 2 agent that also targets fibroblast growth …

Anti-VEGFR2 Inhibitor Shows No Clinical Benefit in Colon Cancer